Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity : Targeting the Microenvironment in Hematological Malignancies: How to Condition both Stromal and Effector Cells to Overcome Cancer SpreadingKRUSCH, M; SALIH, H. R.Current medicinal chemistry. 2011, Vol 18, Num 34, pp 5174-5184, issn 0929-8673, 11 p.Article

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantTHOMAS, Mathew; HUANG, Wei-Sheng; SUNDARAMOORTHI, Raji et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 12, pp 3743-3748, issn 0960-894X, 6 p.Article

Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaABBOTT, Brian L.Clinical therapeutics. 2012, Vol 34, Num 2, pp 272-281, issn 0149-2918, 10 p.Article